RUA — Rua Life Sciences Income Statement
0.000.00%
Last trade - 00:00- £9.00m
- £6.58m
- £6.69m
- 17
- 42
- 64
- 31
Annual income statement for Rua Life Sciences, fiscal year end - September 30th, GBP millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 18 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.53 | 1.63 | 2.18 | 2.19 | 6.69 |
| Cost of Revenue | |||||
| Gross Profit | 1.25 | 1.36 | 1.79 | 1.78 | 5.25 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3.08 | 3.98 | 4.49 | 4.13 | 6.95 |
| Operating Profit | -1.55 | -2.35 | -2.31 | -1.94 | -0.257 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.59 | -2.36 | -2.32 | -2.02 | -0.236 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.45 | -2.07 | -2 | -1.44 | -0.233 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.45 | -2.07 | -2 | -1.44 | -0.218 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.45 | -2.07 | -2 | -1.44 | -0.218 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.082 | -0.093 | -0.09 | -0.043 | -0.004 |